Innovations in Screening Tools for Barrett’s Esophagus and Esophageal Adenocarcinoma

被引:2
作者
Bell M.G. [1 ]
Iyer P.G. [2 ]
机构
[1] Department of Internal Medicine, Mayo Clinic, Rochester, MN
[2] Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
基金
美国国家卫生研究院;
关键词
Barrett’s Esophagus; Esophageal Adenocarcinoma; Screening;
D O I
10.1007/s11894-021-00821-6
中图分类号
学科分类号
摘要
Purpose of Review: Esophageal adenocarcinoma (EAC) is a lethal disease with rapidly rising incidence. Screening for EAC and its metaplastic precursor, Barrett’s esophagus (BE), followed by endoscopic surveillance and endoscopic treatment of dysplasia or early EAC are promising approaches to decreasing EAC incidence and EAC mortality. Historically, screening for EAC has been completed with a traditional per-oral esophagogastroduodenoscopy (EGD); however, this method has limitations including cost, tolerability, and accessibility. For this reason, much effort has been put forward to develop more effective, minimally invasive, and accessible BE and EAC screening tools. The purpose of this review is to describe recent developments of these novel tools. Recent Findings: While endoscopic alternatives such as transnasal endoscopy are cheaper and well tolerated, they have not gained acceptance. Non-endoscopic modalities namely, swallowable cell collection devices coupled with biomarker analysis have been found to have excellent performance characteristics, tolerability, and cost effectiveness. Summary: In this article, we provide an update on innovative developments in EAC/BE screening modalities including transnasal endoscopy, capsule endomicroscopy, swallowable cell collection devices, and exhaled volatile organic compound analyses. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 39 条
  • [1] Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin, 71, 3, pp. 209-249, (2021)
  • [2] Siegel R.L., Miller K.D., Fuchs H.E., Jemal A., Cancer Statistics, 2021, CA Cancer J Clin, 71, 1, pp. 7-33, (2021)
  • [3] Njei B., McCarty T.R., Birk J.W., Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis, J Gastroenterol Hepatol, 31, 6, pp. 1141-1146, (2016)
  • [4] American Cancer Society Cancer Statistics 2021 Report, 62, 3, (2021)
  • [5] Prasad G.A., Wu T.T., Wigle D.A., Buttar N.S., Wongkeesong L.M., Dunagan K.T., Et al., Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus, Gastroenterology, 137, 3, pp. 815-823, (2009)
  • [6] Codipilly D.C., Chandar A.K., Singh S., Wani S., Shaheen N.J., Inadomi J.M., Et al., The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis, Gastroenterology, 154, 8, pp. 2068-86 e5, (2018)
  • [7] Bhat S.K., McManus D.T., Coleman H.G., Johnston B.T., Cardwell C.R., McMenamin U., Et al., Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study, Gut, 64, 1, pp. 20-25, (2015)
  • [8] Sami S.S., Subramanian V., Ortiz-Fernandez-Sordo J., Saeed A., Singh S., Guha I.N., Et al., Performance characteristics of unsedated ultrathin video endoscopy in the assessment of the upper GI tract: systematic review and meta-analysis, Gastrointest Endosc, 82, 5, pp. 782-792, (2015)
  • [9] Peery A.F., Hoppo T., Garman K.S., Dellon E.S., Daugherty N., Bream S., Et al., Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video), Gastrointest Endosc, 75, 5, pp. 945-53 e2, (2012)
  • [10] Shariff M.K., Varghese S., O'Donovan M., Abdullahi Z., Liu X., Fitzgerald R.C., Et al., Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett's esophagus, Endoscopy, 48, 2, pp. 110-116, (2016)